

IRLAB to present at BioStock Life Science Fall Summit on October 26, 2023

Gothenburg, Sweden, October 24, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present at the BioStock Life Science Fall Summit on Thursday, October 26, 2023, in Lund.

Viktor Siewertz, CFO, will present the company at 16:15 CEST on October 26, 2023.

Visit BioStock's event page for more information: www.biostock.se/biostock-life-science-fall-summit-2023/

For more information

Gunnar Olsson, CEO

Phone: +46 70 576 14 02

E-mail: gunnar.olsson@irlab.se

Viktor Siewertz, CFO

Phone: +46 727 10 70 70

E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson's disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson's research group and the discovery of a connection between the brain's neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson's disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB's proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Press Release

Göteborg October 24, 2023



Attachments

[IRLAB to present at BioStock Life Science Fall Summit on October 26, 2023](#)